PF 06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta®): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers Shahrzad Moosavi Troy Borema Reginald Ewesuedo Stuart Harris Jeffrey Levy Thomas B. May Martin Summers Jeffrey S. Thomas Jeffrey Zhang Hsuan-Ming Yao 10.6084/m9.figshare.12280886.v1 https://adisjournals.figshare.com/articles/figure/PF_06881894_a_Proposed_Biosimilar_to_Pegfilgrastim_Versus_US-Licensed_and_EU-Approved_Pegfilgrastim_Reference_Products_Neulasta_Pharmacodynamics_Pharmacokinetics_Immunogenicity_and_Safety_of_Single_or_Multiple_Subcutaneous_Doses_in_Healthy_/12280886 <p>The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).<br></p> <p>© The authors, CC-BY-NC 2020.<b> </b></p> 2020-05-28 12:10:44 Biosimilar Immunogenicity Myelosuppressive chemotherapy Neulasta® Neutropenia Pegfilgrastim PF-06881894 Pharmacodynamics Pharmacokinetics Safety